Fludarabine

Purine analogs, as core medications for the treatment of chronic lymphocytic leukemia (CLL), have continuously driven the iteration of chemotherapy regimens for hematological malignancies over the past three decades, and fludarabine is a landmark variety among them. It inhibits the activities of DNA polymerase, ribonucleotide reductase and DNA primase to block the DNA synthesis and repair of tumor cells and induce apoptosis. Clinically, it is mainly used for first-line and second-line treatment of B-cell chronic lymphocytic leukemia, and can also be combined with other chemotherapeutic drugs for the treatment of indolent non-Hodgkin lymphomas such as follicular lymphoma and mantle cell lymphoma, with the applicable population covering previously untreated and relapsed/refractory adult patients with hematological malignancies.

The global fludarabine market size has long remained around USD 300 million. Affected by the popularization of generic drugs and the launch of new-generation targeted drugs, the growth rate has stayed below 2% in recent years, and the domestic market size is approximately RMB 230 million. The competitive landscape is characterized by the dominance of generic drugs, with the market share of the original research product being less than 15%. Domestic preparation manufacturers are mainly leading enterprises such as Hengrui Medicine and Hisun Pharmaceutical, while the supply of active pharmaceutical ingredients (APIs) is mainly occupied by manufacturers from China and India, among which fludarabine APIs supplied by Chinese enterprises account for more than 62% of the total demand of the global generic drug market.

The original research enterprise of fludarabine is Bayer Group, with the original brand name "Fludara". Its core compound patent in the US market expired in 2006, and the Chinese compound patent also expired in the same year. The main dosage forms approved for the original product include injection (specification: 50mg) and oral tablet (specification: 10mg), among which the injection has been included in the Reference Listed Drug Catalogue of China NMPA and the Reference Listed Drug Catalogue of FDA Orange Book. Up to now, there are 14 fludarabine API registration records on the API registration platform of China CDE, 9 of which have been activated with A status, and more than 20 fludarabine injection and oral preparation varieties have been approved for marketing in China. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for fludarabine API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for enterprises in the links of API R&D, quality research and registration declaration.